Lifecore rises as new manufacturing deal supports growth outlook

Lifecore Biomedical

23/03/2026 11:24

** Shares of drug contract manufacturer Lifecore Biomedical LFCR.O rise 1.4% to $4.07 premarket

** Co says it signed a manufacturing agreement with a new customer in the aesthetics market

** Deal involves taking over U.S. production of an already‑approved sterile injectable drug currently made outside the United States, co says

** Says the transfer should boost supply for the U.S. market and adds to its commercial‑stage portfolio

** Lifecore expects the program to generate commercial revenue within 24 months

** Deal supports co’s target of about 12% average annual revenue growth through 2029, co says

** This is co’s third commercial site‑transfer deal in about five months - LFCR

** Shares up ~10% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))